In Vitro Activities of Caspofungin Compared with Those of Fluconazole and Itraconazole against 3,959 Clinical Isolates of Candida spp., Including 157 Fluconazole-Resistant Isolates
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Caspofungin is an echinocandin antifungal agent with broad-spectrum activity against Candida and Aspergillus spp. The in vitro activities of caspofungin against 3,959 isolates of Candida spp. obtained from over 95 different medical centers worldwide were compared with those of fluconazole and itraconazole. The MICs of the antifungal drugs were determined by broth microdilution tests performed according to the NCCLS method using RPMI 1640 as the test medium. Caspofungin was very active against Candida spp. (MIC at which 90% of the isolates were inhibited [MIC 90 ], 1 μg/ml; 96% of MICs were ≤2 μg/ml). Candida albicans , C. dubliniensis , C. tropicalis , and C. glabrata were the most susceptible species of Candida (MIC 90 , 0.25 to 0.5 μg/ml), and C. guilliermondii was the least susceptible (MIC 90 , >8 μg/ml). Caspofungin was very active against Candida spp., exhibiting high-level resistance to fluconazole and itraconazole (99% of MICs were ≤1 μg/ml). These results provide further evidence for the spectrum and potency of caspofungin activity against a large and geographically diverse collection of clinically important isolates of Candida spp.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comparison of Caspofungin and Amphotericin B for Invasive Candidiasis
Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A. L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Sable, C., Kartsonis, N., & Perfect, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021585 · Cited by 1,380
Current and emerging azole antifungal agents
Sheehan, D. J., Hitchcock, C. A., & Sibley, C. M. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.1.40 · Cited by 1,137 · cited 4×
“In contrast to the triazoles, which are fungistatic for Candida spp., the echinocandins exhibit concentration-dependent fungicidal activity against Candida spp. but not against Aspergillus spp. (6–11, 19).”
BackgroundInfluentialRex, J. H., Pfaller, M. A., Galgiani, J. N., Bartlett, M. S., Espinel-Ingroff, A., Ghannoum, M. A., Lancaster, M., Odds, F. C., Rinaldi, M. G., Walsh, T. J., et al. (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.2.235 · Cited by 855
Self-citationAlly, R., Schürmann, D., Kreisel, W., Carosi, G., Aguirrebengoa, K., Dupont, B., Hodges, M., Troke, P., Romero, A. J., & the Esophageal Candidiasis Study Group (2001) · Clinical Infectious Diseases · doi:10.1086/322653 · Cited by 331
Villanueva, A., Arathoon, E. G., Gotuzzo, E., Berman, R. S., DiNubile, M. J., & Sable, C. A. (2001) · Clinical Infectious Diseases · doi:10.1086/323401 · Cited by 308
Quality Control Limits for Broth Microdilution Susceptibility Tests of Ten Antifungal Agents
Barry, A. L., Pfaller, M. A., Brown, S. D., Espinel-Ingroff, A., Ghannoum, M. A., Knapp, C., Rennie, R. P., Rex, J. H., & Rinaldi, M. G. (2000) · Journal of Clinical Microbiology · doi:10.1128/jcm.38.9.3457-3459.2000 · Cited by 211 · cited 1×
“Quality control. Quality control was performed by testing the NCCLS-recommended strains, C. krusei ATCC 6258 and C. parapsilosis ATCC 22019 ( 4 , 17).”
MethodSelf-citationErnst, E. J., Klepser, M. E., & Pfaller, M. A. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.4.1108-1111.2000 · Cited by 181 · cited 2×
“(7, 8); however, minimum-fungicidal-concentration determinations were not performed in this study.”
BackgroundSelf-citation
Cited by
Resistance to echinocandin-class antifungal drugs.
Perlin, D. S. (2007) · Drug Resistance Updates · doi:10.1016/j.drup.2007.04.002 · Cited by 512
Antifungal Susceptibility Survey of 2,000 Bloodstream Candida Isolates in the United States
Ostrosky-Zeichner, L., Rex, J. H., Pappas, P. G., Hamill, R. J., Larsen, R. A., Horowitz, H. W., Powderly, W. G., Hyslop, N., Kauffman, C. A., Cleary, J., et al. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.10.3149-3154.2003 · Cited by 498
Park, S., Kelly, R., Kahn, J. N., Robles, J., Hsu, M.-J., Register, E., Li, W., Vyas, V., Fan, H., Abruzzo, G., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.8.3264-3273.2005 · Cited by 434
“CAS is a semisynthetic analogue of pneumocandin Bo with broadspectrum activity against a variety of clinically important yeasts and moulds, including Candida and Aspergillus species (8, 18, 32, 33) as well as triazole-resistant strains of Candida (33, 35).”
BackgroundNett, J. E., & Andes, D. R. (2016) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2015.10.012 · Cited by 351
Leaw, S. N., Chang, H. C., Sun, H. F., Barton, R., Bouchara, J.-P., & Chang, T. C. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.44.3.693-699.2006 · Cited by 308
Combination Treatment of Invasive Fungal Infections
Mukherjee, P. K., Sheehan, D. J., Hitchcock, C. A., & Ghannoum, M. A. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.1.163-194.2005 · Cited by 308
Newer Systemic Antifungal Agents: Pharmacokinetics, Safety and Efficacy
Boucher, H. W., Groll, A. H., Chiou, C. C., & Walsh, T. J. (2004) · Drugs · doi:10.2165/00003495-200464180-00001 · Cited by 305
Saravolatz, L. D., Deresinski, S. C., & Stevens, D. A. (2003) · Clinical Infectious Diseases · doi:10.1086/375080 · Cited by 293
Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance.
Cowen, L. E., & Steinbach, W. J. (2008) · Eukaryotic Cell · doi:10.1128/ec.00041-08 · Cited by 285
Current Perspectives on Echinocandin Class Drugs
Perlin, D. S. (2011) · Future Microbiology · doi:10.2217/fmb.11.19 · Cited by 274
“Echinocandin drugs are highly effective against azole-resistant strains of Candida [20–23] and Candida-forming biofilms [24–26], but they are less active against Zygomycetes, Cryptococcus neoformans or Fusarium spp.”
Background(2003) · PubMed · Cited by 240
Balashov, S. V., Park, S., & Perlin, D. S. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01653-05 · Cited by 225
Echinocandins: The newest class of antifungals
Sucher, A. J., Chahine, E. B., & Balcer, H. E. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1m237 · Cited by 213
Cappelletty, D., & Eiselstein‐McKitrick, K. (2007) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.27.3.369 · Cited by 205
Hernandez, S., López-Ribot, J. L., Najvar, L. K., McCarthy, D. I., Bocanegra, R., & Graybill, J. R. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.4.1382-1383.2004 · Cited by 162
“In a large in vitro survey, Pfaller et al. found that only 60% of 420 C. parapsilosis isolates showed susceptibility to caspofungin at 1 g/ml versus 96% of more than 3,000 isolates of the other species tested, including 99% of 2,453 C. albicans isolates ( 11 ).”
ResultThe echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy
Wiederhold, N. P., & Lewis, R. E. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.8.1313 · Cited by 144
Niimi, K., Maki, K., Ikeda, F., Holmes, A. R., Lamping, E., Niimi, M., Monk, B. C., & Cannon, R. D. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.4.1148-1155.2006 · Cited by 134
“albicans Candida species, and azole-resistant Candida species (3, 6, 28, 33).”
BackgroundDesnos-Ollivier, M., Bretagne, S., Raoux, D., Hoinard, D., Dromer, F., & Dannaoui, E. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00088-08 · Cited by 132
Takakura, S. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh053 · Cited by 117
Acquired Echinocandin Resistance in a Candida krusei Isolate Due to Modification of Glucan Synthase
Kahn, J. N., Garcia-Effron, G., Hsu, M.-J., Park, S., Marr, K. A., & Perlin, D. S. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00067-07 · Cited by 118
Effects of Caspofungin against Candida guilliermondii and Candida parapsilosis
Barchiesi, F., Spreghini, E., Tomassetti, S., Della Vittoria, A., Arzeni, D., Manso, E., & Scalise, G. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00111-06 · Cited by 98
Fleischhacker, M., Radecke, C., Schulz, B., & Ruhnke, M. (2008) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-007-0411-4 · Cited by 78
Clancy, C. J., Huang, H., Cheng, S., Derendorf, H., & Nguyen, M. H. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00291-06 · Cited by 73
Cavalheiro, M., Costa, C., Silva-Dias, A., Miranda, I. M., Wang, C., Pais, P., Pinto, S. N., Mil-Homens, D., Sato-Okamoto, M., Takahashi-Nakaguchi, A., et al. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00995-18 · Cited by 42
The assimilation of different carbon sources in Candida albicans: Fitness and pathogenicity
Lok, B., Adam, M. A. A., Kamal, L. Z. M., Chukwudi, N. A., Sandai, R., & Sandai, D. (2021) · Medical Mycology · doi:10.1093/mmy/myaa080 · Cited by 39
Metadata
- Authors
- Pfaller, M. A., Diekema, D. J., Messer, S. A., Hollis, R. J., & Jones, R. N.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2003-03
- Volume
- 47
- Issue
- 3
- Pages
- 1068-1071
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2158001207
- Cited by
- 154
- References
- 7
- FWCI
- 15.09
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.